Why Formulation Technologies are Critical to the Success of the Next Generation of Small Molecule Oral Drugs
Summary: A connected, data-driven approach to managing bioavailability challenges in new chemical entities (NCEs) is the best way to improve the odds that a molecule will advance to in-human trials. By taking advantage of modern screening technologies to collect and leverage molecular data early on, drug developers can bridge the gap between molecule discovery and dose form selection – two critical processes that are often executed at a problematic distance from one another. It’s a process called Parallel Screening, and this executive summary delves into how this method is the most efficient way of maximizing a NCE’s chances of making it to Phase 1.